Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 9,459 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,459 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.23, for a total value of $872,403.57. Following the sale, the senior vice president owned 15,312 shares of the company’s stock, valued at approximately $1,412,225.76. This represents a 38.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total value of $53,597.60.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total value of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.95, for a total value of $128,467.65.

Oruka Therapeutics Price Performance

Shares of ORKA stock traded down $3.73 during trading hours on Tuesday, reaching $92.20. 784,617 shares of the company’s stock were exchanged, compared to its average volume of 741,278. Oruka Therapeutics, Inc. has a 1 year low of $14.66 and a 1 year high of $115.51. The stock’s fifty day moving average price is $95.87 and its two-hundred day moving average price is $72.78.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ORKA has been the topic of a number of research reports. Mizuho set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, September 3rd. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Guggenheim reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. UBS Group raised their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $133.00.

Hedge Funds Weigh In On Oruka Therapeutics

A number of large investors have recently bought and sold shares of the business. Engineers Gate Manager LP acquired a new stake in Oruka Therapeutics in the second quarter valued at approximately $350,000. Arizona State Retirement System raised its stake in shares of Oruka Therapeutics by 45.0% during the 2nd quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock worth $825,000 after buying an additional 2,691 shares during the period. Nykredit A S purchased a new position in shares of Oruka Therapeutics during the 2nd quarter valued at approximately $29,000. Braidwell LP purchased a new position in shares of Oruka Therapeutics during the 2nd quarter valued at approximately $26,473,000. Finally, Natural Investments LLC acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at $202,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.